Announced details
Treatment of patients with distressing chronic tinnitus
Evaluate the app’s efficacy and safety when used for 16 weeks
Kyorin Pharmaceutical and SUSMED,Inc. are jointly developing the app. Kyorin Pharmaceutical provides expertise in the disease area, clinical development capabilities and sales capabilities, while SUSMED,Inc. provides a development platform for treatment apps, a clinical trial system and research and development expertise.
Head office: Chuo-ku, Tokyo; Representative Director and President: Ueno Taro (上野太郎). SUSMED,Inc. is a research and development company advancing digital healthcare. It develops treatment apps for conditions including insomnia and provides clinical development support systems.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Clinical Practice Guideline for Tinnitus (Japanese Audiological Society, General Incorporated Association)
Web-Based Survey of Tinnitus Care in Japan (Audiology Japan 67:548-557, 2024)
| Item | Details |
|---|---|
| Names of Products / Services Covered | KRP-DT123/SMD403, Tinnitus treatment app |
| Counterparty | SUSMED,Inc. |
| Counterparty overview | Head office: Chuo-ku, Tokyo; Representative Director and President: Ueno Taro (上野太郎). SUSMED,Inc. is a research and development company advancing digital healthcare. It develops treatment apps for conditions including insomnia and provides clinical development support systems. |
| Relationship with the Company | Kyorin Pharmaceutical and SUSMED,Inc. are jointly developing the app. Kyorin Pharmaceutical provides expertise in the disease area, clinical development capabilities and sales capabilities, while SUSMED,Inc. provides a development platform for treatment apps, a clinical trial system and research and development expertise. |
| Applicable area | Treatment of patients with distressing chronic tinnitus |
| Quantitative Effects | Evaluate the app’s efficacy and safety when used for 16 weeks |
| Source | Clinical Practice Guideline for Tinnitus (Japanese Audiological Society, General Incorporated Association), Web-Based Survey of Tinnitus Care in Japan (Audiology Japan 67:548-557, 2024) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The companies aim to evaluate the app’s efficacy and safety in patients with distressing chronic tinnitus and provide a new treatment option for patients suffering from tinnitus.